Scholarlink

Background <p>Neonatal jaundice is one of the most prevalent illnesses in neonates, requiring care and treatment. Fenofibrate is a lipid-lowering drug that enhances the conjugation and excretion of bilirubin. Previous studies have suggested the usefulness of fenofibrate for the treatment of indirect hyperbilirubinemia in neonates.</p> Objective <p>To evaluate the role of fenofibrate in neonates with neonatal jaundice near the level of phototherapy.</p> Patients and Methods <p>seventy- five full-term infants with neonatal jaundice near the level of phototherapy were randomly divided into three groups: single-dose group: 25 neonates received a single oral dose of 10&#xa0;mg/kg of non-micronized fenofibrate and an oral dose of an equivalent amount of distilled water as a placebo. Double-dose group: 25 neonates received two oral doses of 10&#xa0;mg/kg non-micronized fenofibrate. The control group included 25 neonates who received two oral doses of an equivalent amount of distilled water as a placebo.</p> Results <p>The double-dose group had the highest significant drop in transcutaneous bilirubin (TCB) starting from 12 to 48&#xa0;h after drug intake and the highest drop in total serum bilirubin (TSB) starting from 12&#xa0;h to the 5th day in comparison to the single-dose group and the controls. The single-dose and double-dose groups had a significantly lower incidence of the need for admission and phototherapy than the control group (<i>P</i> = 0.009). The double-dose group had a significantly higher incidence of drug side effects than the single-dose group (<i>P</i> &lt; 0.001), mainly in the form of abdominal distension (P = 0.008); however, only minor treatment was required.</p> Conclusion <p>Fenofibrate can significantly decrease bilirubin levels in full-term neonates with neonatal jaundice near the level of phototherapy, with no need for admission and phototherapy management. The drug was well-tolerated and safe. Double-dose treatment with fenofibrate significantly lowered TSB with no significant increase in side effects when compared to the single-dose group.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploring the role of peroxisome proliferator- activated receptor agonists (fenofibrate) in neonatal jaundice prevention

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月29日

查看全文
  • Rania Mohamed Abdou,
  • Nancy Mohamed Abo Shady,
  • Hala Sedky Gomaa Rohaim,
  • Mariam John Amin Ibrahim

摘要

Background

Neonatal jaundice is one of the most prevalent illnesses in neonates, requiring care and treatment. Fenofibrate is a lipid-lowering drug that enhances the conjugation and excretion of bilirubin. Previous studies have suggested the usefulness of fenofibrate for the treatment of indirect hyperbilirubinemia in neonates.

Objective

To evaluate the role of fenofibrate in neonates with neonatal jaundice near the level of phototherapy.

Patients and Methods

seventy- five full-term infants with neonatal jaundice near the level of phototherapy were randomly divided into three groups: single-dose group: 25 neonates received a single oral dose of 10 mg/kg of non-micronized fenofibrate and an oral dose of an equivalent amount of distilled water as a placebo. Double-dose group: 25 neonates received two oral doses of 10 mg/kg non-micronized fenofibrate. The control group included 25 neonates who received two oral doses of an equivalent amount of distilled water as a placebo.

Results

The double-dose group had the highest significant drop in transcutaneous bilirubin (TCB) starting from 12 to 48 h after drug intake and the highest drop in total serum bilirubin (TSB) starting from 12 h to the 5th day in comparison to the single-dose group and the controls. The single-dose and double-dose groups had a significantly lower incidence of the need for admission and phototherapy than the control group (P = 0.009). The double-dose group had a significantly higher incidence of drug side effects than the single-dose group (P < 0.001), mainly in the form of abdominal distension (P = 0.008); however, only minor treatment was required.

Conclusion

Fenofibrate can significantly decrease bilirubin levels in full-term neonates with neonatal jaundice near the level of phototherapy, with no need for admission and phototherapy management. The drug was well-tolerated and safe. Double-dose treatment with fenofibrate significantly lowered TSB with no significant increase in side effects when compared to the single-dose group.